Of interest in this context is the observation that knockdown of NEAT1 renders K562 CML cells more sensitive to Imatinib and proteasome inhibitors, since combinatorial treatment leads to accelerated apoptosis of K562 cells. This evidence concerns the gene NEAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.